HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory
Credit Suisse: High Probability Of 2024 Delay
Novartis is sticking to its plan to continue fighting HEC Pharm in court, after it recently lost a key decision for its Gilenya (fingolimod) blockbuster treatment for multiple sclerosis.
